Iroko Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Iroko Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C2798
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Iroko Pharmaceuticals LLC (Iroko) is a pharmaceutical company that develops treatment options for responsible pain management. The company’s products comprise low dose Nonsteroidal anti-inflammatory drugs such as meloxicam, indomethacin, and diclofenac that are in various stages of nonclinical and clinical development. It offers products in capsules and tablets dosage forms. Iroko utilizes SoluMatrix fine particle technology to produce NSAIDs as submicron particles. The company conducts research in advancing the science of analgesia in the areas of pain management. It markets its products in the US and abroad. Iroko is headquartered in Philadelphia, Pennsylvania, the US.

Iroko Pharmaceuticals LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Iroko Pharma To Raise US$75 Million In Venture Financing 10
Licensing Agreements 11
Iroko Pharma Enters into Licensing Agreement with Laboratorios Saval 11
Iroko Pharma Enters into Licensing Agreement with Litha Pharma for ZORVOLEX 12
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 13
Iroko Pharma Enters into Licensing Agreement with Landsteiner Scientific for Zorvolex 14
Iroko Pharma Expands Licensing Agreement with Calox for Zorvolex 15
Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 16
Iroko Pharma Enters Licensing Agreement With Algorithm For Zorvolex Capsules 17
Iroko Pharma Enters Licensing Agreement With Fahrenheit For Zorvolex Capsules 18
Equity Offering 19
Iroko Pharma Withdraws IPO Of Shares For Up To US$145 Million 19
Iroko Pharmaceuticals LLC – Key Competitors 21
Iroko Pharmaceuticals LLC – Key Employees 22
Iroko Pharmaceuticals LLC – Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iroko Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 8
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Iroko Pharma To Raise US$75 Million In Venture Financing 10
Iroko Pharma Enters into Licensing Agreement with Laboratorios Saval 11
Iroko Pharma Enters into Licensing Agreement with Litha Pharma for ZORVOLEX 12
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 13
Iroko Pharma Enters into Licensing Agreement with Landsteiner Scientific for Zorvolex 14
Iroko Pharma Expands Licensing Agreement with Calox for Zorvolex 15
Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 16
Iroko Pharma Enters Licensing Agreement With Algorithm For Zorvolex Capsules 17
Iroko Pharma Enters Licensing Agreement With Fahrenheit For Zorvolex Capsules 18
Iroko Pharma Withdraws IPO Of Shares For Up To US$145 Million 19
Iroko Pharmaceuticals LLC, Key Competitors 21
Iroko Pharmaceuticals LLC, Key Employees 22

List of Figures
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Iroko Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Enercon Services Inc-エネルギー分野:企業M&A・提携分析
    Summary Enercon Services, Inc. (Enercon) is a diversified consulting company offering architectural engineering, environmental, technical and management services. Its offerings include licensing, operations, permitting, construction, decommissioning, and staff augmentation, cyber security and regula …
  • Debt Resolve Inc (DRSV):企業の財務・戦略的SWOT分析
    Summary Debt Resolve Inc (Debt Resolve) is a technology company that offers cloud-based software and services. The company develops and markets patent-based web collection technologies. It provides solutions for non-payment of bills, debts, damages and other financial disputes. Debt Resolve also off …
  • Helmerich & Payne Inc (HP):企業の財務・戦略的SWOT分析
    Helmerich & Payne Inc (HP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Ircon International Limited:企業の戦略・SWOT・財務情報
    Ircon International Limited - Strategy, SWOT and Corporate Finance Report Summary Ircon International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Canada Goose Holdings Inc (GOOS):企業の財務・戦略的SWOT分析
    Canada Goose Holdings Inc (GOOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • SmarTone Telecommunications Holdings Ltd (315):企業の財務・戦略的SWOT分析
    SmarTone Telecommunications Holdings Ltd (315) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • ZyGEM NZ Ltd:医療機器:M&Aディール及び事業提携情報
    Summary ZyGEM NZ Ltd (ZyGEM), a subsidiary of MicroGEM International PLC is a drug development company that develops and technologies for life science, agricultural and horticultural industries. The company produces DNA extraction products, and enzymes used in diagnostics, molecular biology and indu …
  • Ameritas Mutual Holding Company:企業の戦略的SWOT分析
    Ameritas Mutual Holding Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Neptune Marine Services Ltd (NMS):企業の財務・戦略的SWOT分析
    Summary Neptune Marine Services Ltd (NMSL), a subsidiary of MTQ Corp Ltd, is an engineering solutions provider. The company's services include commercial diving; manufacturing, testing and assembly; dry underwater welding; survey, geophysical and geotechnical services, asset integrity services, ROV …
  • Societe Generale S.A.:企業の戦略・SWOT・財務分析
    Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report Summary Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Lahey Hospital and Medical Center:企業の戦略的SWOT分析
    Lahey Hospital and Medical Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Artios Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Artios Pharma Ltd (Artios Pharma) is an independent company that focuses on the development of DNA Damage Response (DDR) therapies to treat cancer. The company has in-licensed its lead DDR programme, DNA polymerase theta (PolO) from Cancer Research Technology (CRT), which target proteins tha …
  • The J. R. Simplot Co:企業の戦略・SWOT・財務情報
    The J. R. Simplot Co - Strategy, SWOT and Corporate Finance Report Summary The J. R. Simplot Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sumitomo Mitsui Trust Holdings Inc:企業の戦略・SWOT・財務分析
    Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Mitsui Trust Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Metals X Limited:企業の戦略・SWOT・財務情報
    Metals X Limited - Strategy, SWOT and Corporate Finance Report Summary Metals X Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Aratana Therapeutics Inc (PETX):企業の財務・戦略的SWOT分析
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • Wilson Therapeutics AB (WTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Wilson Therapeutics AB (Wilson Therapeutics), a subsidiary of Alexion Pharma Nordics AB, is a biopharmaceutical company that develops novel therapies for patients with rare copper-mediated disorders. The company’s lead product includes WTX101 is a copper-protein-binding agent, which is used …
  • Symphogen AS-製薬・医療分野:企業M&A・提携分析
    Summary Symphogen A/S (Symphogen) is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics to enhance the lives of patients with cancer and ot …
  • Competitive Power Ventures Inc:企業の戦略的SWOT分析
    Competitive Power Ventures Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Eurobio Scientific SA (ALERS):企業の製品パイプライン分析
    Summary Eurobio Scientific SA (Eurobio), formerly Diaxonhit SA, a subsidiary of Hellenic Petroleum SA, is a biotechnology company that provides diagnostic products. The company provides products such as TQS, used in treatment of teanus and BJI InoPlex, used for the treatment of prosthetic infection. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆